Sekundarni jezik: |
Angleški jezik |
Sekundarni naslov: |
Clinical course of HER-2 positive breast cancer patients |
Sekundarni povzetek: |
Breast cancer is the most frequent cancer in women. The course and efficiency of breast cancer treatment are influenced by several factors. The expression of HER-2 protein and HER-2 gene is gaining in strength in breast cancer management. The aim of our study was to compare the course of HER-2 positive with HER-2 negative disease. In median time of 2.5 years DFS (disease-free-survival) of patients with HER-2 positive tumours was 76.1%, and 93.4% for patients with HER-2 negative disease. HER-2 status was the strongest prognostic factor for DFS (p |
Sekundarne ključne besede: |
Breast Neoplasms;Genetics;Neoplasm Staging;Genes, Erbb-2;Survival Analysis;Disease-Free Survival;Retrospective Studies;Preživetje, analiza;Brez bolezni, preživetje;Dojka, novotvorbe;Geni erB-2;Novotvorba, stadij;Retrospektivne študije; |
URN: |
URN:NBN:SI |
Komentar vira: |
Soavtorji: Š. Fink, S. Frković Grazio, H. Lešničar, A. Sadikov in T. Čufer;
BSDOCID143369;
|
Strani: |
str. 94-98 |
Letnik: |
ǂLetn. ǂ12 |
Zvezek: |
ǂšt. ǂ2 |
Čas izdaje: |
2008 |
ID: |
10957171 |